Gamida Cell Ltd.
GMDADelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001600847
Gamida Cell Ltd. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Feb 2, 2024; 52 institutions reported holding it in 13F filings for Q1 2024, worth $697.9K in total; ARK Invest was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Gamida Cell Ltd. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Gamida Cell Ltd., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Moch Kenneth I | Director | 232,300 | Feb 2, 2024 | 0 |
| Wills Stephen T | Director | 256,177 | Feb 2, 2024 | 0 |
| Adams Julian | Director | 423,750 | Feb 2, 2024 | 0 |
| Tomasello Shawn | Director | 241,977 | Feb 2, 2024 | 0 |
| Korfin Michele Ilene | COO/CHIEF COMMERCIAL OFFICER | 702,981 | Feb 2, 2024 | 0 |
| Patterson Joshua F. | GENERAL COUNSEL | 855,461 | Feb 2, 2024 | 0 |
| Simantov Ronit | CMO & CHIEF SCIENTIFIC OFFICER | 655,896 | Feb 2, 2024 | 0 |
| Borrello Ivan M. | Director | 232,300 | Feb 2, 2024 | 0 |
| Jenkins Abigail L. | President and CEO | 375,142 | Oct 20, 2023 | 0 |
| Blank Jeremy | Director | 4,000 | Aug 15, 2023 | 0 |
| Coelho Mary Theresa | Chief Financial Officer | – | Jun 14, 2023 | 0 |
| Blum Robert I | Director | 96,500 | Feb 10, 2023 | 0 |
| Halevi-Davidov Naama | Director | 32,300 | Feb 10, 2023 | 0 |
| Lankry Shai | Chief Financial Officer | 145,425 | Feb 10, 2023 | 0 |
| Cohen-Dayag Anat | Director | 32,300 | Feb 10, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 4, 2022 (view filing) | Sep 30 | 4 days | Wills Stephen TDirector | PPurchase | +9.68K | $1.55 | +$15.0K | +483.8%11.7K after | |
| Oct 4, 2022 (view filing) | Sep 30 | 4 days | Tomasello ShawnDirector | PPurchase | +9.68K | $1.55 | +$15.0K | +483.8%11.7K after | |
| Oct 4, 2022 (view filing) | Sep 30 | 4 days | Blum Robert IDirector | PPurchase | +50.0K | $1.55 | +$77.5K | +2,500.0%52.0K after | |
| Oct 4, 2022 (view filing) | Sep 30 | 4 days | Jenkins Abigail L.President and CEO | PPurchase | +16.1K | $1.55 | +$25.0K | +6.5%266.1K after |